TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

115 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

107 studies on the map

Molecular Signatures of Cutaneous Dupilumab Response — University of California, San Francisco, San FranciscoA Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease — Research Site, BirminghamGenetic Variation in IgG in Alpha 1 Antitrypsin Deficiency — University of Alabama at Birmingham, BirminghamEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype — University of Alabama at Birmingham- Site Number : 8400003, BirminghamA Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) — Arizona Liver Health, ChandlerA Study to Learn About Study Medicine Called PF-08049820 in People With Eczema — Northridge Clinical Trials, NorthridgeA Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH — GSK Investigational Site, ArcadiaA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — UAB Lung Health Center, BirminghamA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) — Research Site, FoleyEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaA Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health, ChandlerCardamom and Topical Roseomonas in Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaThe Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) — UCSF Airway Clinical Research Center, San FranciscoDepemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) — GSK Investigational Site, SheffieldTo Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment — DM Clinical Research - Phoenix, PhoenixA Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis — Investigational Site, Fountain ValleyA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) — First OC Dermatology, IrvineDupilumab De-escalation in Pediatric Atopic Dermatitis — Johns Hopkins Univerisity, BaltimoreImpact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD) — Cincinnati Children's Hospital Medical Center, CincinnatiA Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis — Mountain West Derm - Blackhart PLLC dba Skin Cancer and Dermatology Institute, PhoenixA Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis — Akero Clinical Study Site, BirminghamNon-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) — National Institutes of Health Clinical Center, BethesdaA Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH) — Arizona Liver Health - Chandler, ChandlerA Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) — 89bio Clinical Study Site, BirminghamA Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis — Inmagene Site 1, LancasterHuman Models of Selective Insulin Resistance: Alpelisib, Part I — Columbia University Irving Medical Center, New YorkMechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease — Ann & Robert H Lurie Children's Hospital of Chicago, ChicagoStudy to Evaluate Soquelitinib in Participants With Moderate to Severe AD — Corvus Clinical Trials, South San FranciscoPh 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 — Clinical Site 101, Fair LawnFibrosis Lessens After Metabolic Surgery — Banner Health Center, PhoenixMulti-Center Clean Air Randomized Controlled Trial in COPD — University of Alabama, Lung Health Center, BirminghamBreathe Easier With Tadalafil Therapy for Dyspnea in COPD-PH — Rocky Mountain Regional VA Medical Center, Aurora, CO, AuroraTreatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome — Icahn School of Medicine at Mount Sinai, New YorkA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH — 89bio Clinical Study Site, BirminghamA Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis — Hamilton Research, LLC, AlpharettaEfficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype — Chandler Clinical Research Trials- Site Number : 8400025, ChandlerLebrikizumab in Moderate-to-severe Atopic Dermatitis — Physioseq USA - CA, FolsomA Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH — GSK Investigational Site, ChandlerA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockRademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) — University of Alabama at Birmingham Lung Health Center, BirminghamA Study of BBT002 in Healthy Volunteers (HVs) and in Adult Patients With Chronic Obstructive Pulmonary Disease (COPD) or Chronic Rhiosininusitis With Nasal Polyps (CRSwNP) — Equity Medical Bowling Green, Bowling GreenDepemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) — GSK Investigational Site, Loxahatchee GrovesThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — University of Pittsburgh Medical Center, PittsburghEthnic Differences in Mechanisms of Action of Dupilumab — University of Michigan, Ann ArborA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamSafety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Red River Research Partners, FargoA Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease — Research Site, AthensEvaluating the Pharmacokinetics and Safety of Miricorilant — Site# 433, San AntonioFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Anaheim Clinical Trials, LLC, AnaheimA Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD — SEC Clinical Research, LLC, DothanBicalutamide Therapy in Young Women With NAFLD and PCOS — University of California San Francisco, San FranciscoA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — Sitryx Clinical Site, Arkansas CityCompare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators — The University of Tennessee Graduate School of Medicine, KnoxvilleA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease — University of Alabama at Birmingham Lung Health Center, BirminghamA Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease — University of Alabama at Birmingham, BirminghamFeasibility of Semaglutide in Advanced Lung Disease — University of Pennsylvania Perelman School of Medicine, PhiladelphiaA Study to Evaluate Solrikitug in Participants With COPD (ZION) — University of Alabama at Birmingham Hospital, BirminghamA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) — University of California, San Diego: Dermatology Clinical Trials Unit, San DiegoA Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis — AllerVie Clinical Research, BirminghamA Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab — Physioseq, LLC /ID# 267266, SacramentoA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamEvaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis — First OC Dermatology, Fountain ValleyA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) — ALS Global, IrvingA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — Nektar Investigative Site, St. PetersburgA Study of WIN378 in Participants With Moderate to Severe COPD (Sirius) — WB Contracted Clinical Research Site, Miami LakesMilk Thistle Clinical Trial in Pediatric NAFLD — University Hospitals Cleveland Medical Center, ClevelandeValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation — GSK Investigational Site, DoralDigoxin In NASH (CODIN) — Yale New Haven Health, New HavenA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH — Akero Clinical Study Site, BirminghamLIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis — University of Alabama at Birmingham, BirminghamLIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis — The Institute for Liver Health II DBA Arizona Clinical Trials, PeoriaA Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH — GSK Investigational Site, ArcadiaThe Cardiovascular Consequences of Sleep Apnea Plus COPD (Overlap Syndrome) — UCSD Sleep Research, La JollaA Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis — Atd002 52021, OceansideStudy of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis — Enveda Investigative Site, BirminghamStudy to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH — University of California San Diego, La JollaA Study of Efimosfermin Alfa in Adults With Hepatic Impairment — GSK Investigational Site, RialtoEffect of Insulin Lowering on Lipogenesis — Columbia University Irving Medical Center, New YorkEffect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study) — Univeristy of Colorado Anschutz Medical Campus, AuroraA Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis — Allervie Clinical Research, BirminghamEffects of Treatments on Atopic Dermatitis — National Institutes of Health Clinical Center, Bethesda: Vascular Function in Health and Disease — George E Wahlen VA Medical Center, Salt Lake CityHyper Polarized Xenon-129 MRI vs Xenon-133 Scintigraphy — University of Virginia Health System, CharlottesvilleLung and Bone Marrow Transplantation for Lung and Bone Marrow Failure — UPMC Presbyterian, PittsburghLow-Dose Pioglitazone in Patients With NASH (AIM 2) — University of Florida, GainesvilleHyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease — University of Kansas Medical Center, Kansas CityFeasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD — University of Tennessee Medical Center, KnoxvillePulmonary Hypertension SOLAR — Duke University Medical Center, DurhamEstrogen Administration for the Treatment of NASH in Postmenopausal Women — Massachusetts General Hospital, BostonUsing Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis — Lurie Children's Hospital/Northwestern University, ChicagoTrial to Determine Effective Aspirin Dose in COPD — Johns Hopkins Bayview Medical Center, BaltimoreEffect of Ensifentrine on Sputum Markers of Inflammation in COPD — University of Alabama at Birmingham, BirminghamDupixent and Narrowband UVB for Atopic Dermatitis — Eczema Treatment Center of New Jersey, East WindsorQuantifying Hepatic Mitochondrial Fluxes in Humans — Texas Diabetes Institute - University Health System, San AntonioRandomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant — Virginia Commonwealth University, RichmondA Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition — Arizona Liver Health, ChandlerThyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans — Harry S. Truman Memorial, Columbia, MO, ColumbiaA Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis — Arkansas Research Trials, North Little RockA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — Cahaba Dermatology & Skin Health Center, BirminghamA Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) — Research Site, CullmanEvaluation of Miricorilant on Liver Fat in Patients With MASLD — University of Missouri, ColumbiaPlatform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis — Novartis Investigative Site, BirminghamInhaled Treprostinil (Tyvaso Nebulizer) For COPD Patients With Hypoxemia — Duke Asthma Allergy and Airway Center, DurhamA Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. — University of Alabama at Birmingham - School of Medicine- Site Number : 8400003, BirminghamClinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD — University of Alabama, Birmingham